Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Assets: 2023-2025

Historic Other Non-Current Assets for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.3 million.

  • Tonix Pharmaceuticals Holding's Other Non-Current Assets rose 36.59% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 36.59%. This contributed to the annual value of $951,000 for FY2024, which is 15.77% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Other Non-Current Assets stood at $1.3 million, which was up 39.53% from $931,000 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Other Non-Current Assets' 5-year high stood at $1.3 million during Q3 2025, with a 5-year trough of $292,000 in Q2 2023.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Other Non-Current Assets had a median value of $951,000 in 2024 and averaged $892,727.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Other Non-Current Assets showed a top increase of 229.11% in 2024 and a maximum decrease of 15.77% in 2024.
  • Tonix Pharmaceuticals Holding's Other Non-Current Assets (Quarterly) stood at $1.1 million in 2023, then fell by 15.77% to $951,000 in 2024, then soared by 36.59% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $931,000 for Q2 2025, and $910,000 during Q1 2025.